The TARGET Study.

The TARGET Study

Cancer Therapies & Ablation / TheraSphere / Proven Results / The TARGET Study

 

A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.

Lam, Marnix. A Global Study of Advanced Dosimetry in the Treatment of Hepatocellular Carcinoma with Yttrium-90 Glass Microspheres: Analyses from the TARGET Study. Presented at SIR. March 25, 2021

 

Study Objective

Establish the relationships between:

  • Normal tissue adsorbed dose (NTAD) and occurrence of grade 3 or higher hyperbilirubinemia
  • Tumor absorbed dose (TAD) and Objective Response Rate (ORR)
  • TAD and Overall Survival (OS)
 

Study Design

Key Patient Characteristics

  • Mainly Intermediate and Advanced HCC: 33% BCLC B and 55% BCLC C
  • 7cm median target lesion
  • 33% PVT

Dosimetry Approach

  • Investigator review of patient chart and dosimetry calculation
  • Retrospective dosimetry evaluation with multi-compartment approach using Simplicit90Y™ personalized dosimetry software to determine TAD and NTAD

Results

Tumor Absorbed Dose Was Predictive of Response1,2

Tumor Absorbed Dose Was Predictive of Overall Survival

Low Rate of ≥ Grade 3 Hyperbilirubinemia Confirms Safety of TARGET Study

 colored background

 

Study Takeaways

Dose Matters

short white line.
Deliver the highest dose to the tumor that is safely possible to maximize patient response and improve survival


Predictability

short white line.
Predictable results across 8 countries using multi-compartmental dosimetry using Simplicit90Y™ personalized dosimetry software


Consistency

short white line.
Like the LEGACY study and DOSISPHERE-01 trial results, the TARGET study reinforces the association between higher tumor absorbed dose and clinical outcomes


Simplicit90Y™ Personalized Dosimetry Software

Simplicit90Y is the only Y-90 personalized dosimetry software with FDA 510K  clearance, designed specifically for TheraSphere™ Y-90 Glass Microspheres. Simplicit90Y was developed to accelerate dosimetry planning and improve your Y-90 Selective Internal Radiation Therapy (SIRT) workflow.

Simplicit90Y™ Personalized Dosimetry Software image.

Intended Use (US Only)
Simplicit90Y™ is intended to be used by trained medical professionals for TheraSphere™ pre-treatment dosimetry planning and post-treatment dosimetry evaluation following Y90 treatment. Simplicit90Y is a medical image and information management system that is intended to receive, transmit, store, retrieve, display and process digital medical images, as well as create, display and print reports from those images. The medical modalities of these medical imaging systems include, but are not limited to, CT, MRI, SPECT and PET. Simplicit90Y provides the user with the means to display, register and fuse medical images from multiple modalities. Simplicit90Y provides tools to create, transform, and modify contours for the user to define objects in medical image volumes for use in TheraSphere pre-treatment dosimetry planning and for post-treatment dosimetry. The objects include, but are not limited to, tumors and normal tissues. For post-Yttrium-90 (Y90) treatment, Simplicit90Y should only be used for the retrospective determination of dose and should not be used to prospectively calculate dose or for the case where there is a need for retreatment using Y90 microspheres.

Indication for Use (US Only)
Simplicit90Y is a standalone software device that is used by trained medical professionals as a tool to aid in evaluation and information management of digital medical images. Simplicit90Y supports the reading, rendering and display of a range of DICOM compliant imaging and related formats including but not limited to CT, PT, NM, SPECT, MR, SC, RTSS. Simplicit90Y enables the saving of sessions in a proprietary format as well as the export of formats including CSV and PDF files. Simplicit90Y is indicated, as an accessory to TheraSphere, to provide pre-treatment dosimetry planning support including Lung Shunt Fraction estimation (based on planar scintigraphy) and liver single-compartment MIRD schema dosimetry, in accordance with TheraSphere labelling. Simplicit90Y provides tools to create, transform, and modify contours/Regions of Interest for calculation of Lung Shunt Fraction and Perfused Volume. Simplicit90Y includes features to aid in TheraSphere dose vial selection, dose vial ordering and creation of customizable reports. Simplicit90Y is indicated for post-treatment dosimetry and evaluation following Yttrium-90 (Y-90) microsphere treatment. Simplicit90Y provides tools to create, transform, and modify contours/Regions of Interest for the user to define objects in medical image volumes to support TheraSphere post-Y-90 treatment calculation and evaluation. The objects include, but are not limited to, tumors and normal tissues, and liver volumes. Simplicit90Y is indicated for registration, fusion display and review of medical images allowing medical professionals to incorporate images, such as CT, MRI, PET, CBCT and SPECT in TheraSphere Yttrium-90 (Y-90) microspheres pre-treatment planning and post-Y-90 treatment evaluation For post-Yttrium-90 (Y-90) treatment, Simplicit90Y should only be used for the retrospective determination of dose and should not be used to prospectively calculate dose or for the case where there is a need for retreatment using Y-90 microspheres. PI-994110-AA

 

PI-991704-AA

Top